Mechanism of increased sensitivity to etoposide in a mitomycin C-resistant human bladder cancer cell line

Hong Xia, Richard J. Bleicher, Vicram Gupta, Howard A. Zaren, Shivendra V. Singh

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The mechanism of increased sensitivity to etoposide (VP-16) in a human bladder cancer cell line (J82/MMC-2), which is > 9-fold more resistant to mitomycin C (MMC) compared with parental cells (J82/WT), was investigated. Colony formation assays, following 1 hr drug exposure, revealed that about a 2.2-fold higher concentration of VP-16 was required to kill 50% of the J82/WT cell line compared with J82/MMC-2. The MTT assays, following continuous drug exposure, also showed that the J82/MMC-2 cell line was significantly more sensitive to VP-16 compared with J82/WT. Accumulation of VP-16 was significantly higher in the J82/MMC-2 cell line compared with J82/WT at every drug concentration tested. Likewise, intracellular VP-16 retention was significantly higher in the J82/MMC-2 cell line compared with J82/WT when drug uptake was measured as a function of varying incubation time and at a fixed VP-16 concentration. The efflux of VP-16 from the J82/MMC-2 cell line was equivalent to that from J82/WT. In agreement with the results of drug uptake studies, the levels of VP-16-induced protein-DNA complexes were markedly higher in the J82/MMC-2 cell line compared with J82/WT. The catalytic activity of topoisomerase II (topo II) in 0.35 M NaCl nuclear extract of J82/WT cells was equivalent to that of J82 results suggest that the mechanism responsible for the collateral sensitivity of the J82/MMC-2 cell line to VP-16 may be attributable to a relatively higher drug accumulation in this cell line compared with parental cells.

Original languageEnglish (US)
Pages (from-to)606-611
Number of pages6
JournalInternational Journal of Cancer
Volume70
Issue number5
DOIs
StatePublished - Apr 17 1997

Fingerprint

Mitomycin
Etoposide
Urinary Bladder Neoplasms
Cell Line
Pharmaceutical Preparations
Type II DNA Topoisomerase
DNA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Mechanism of increased sensitivity to etoposide in a mitomycin C-resistant human bladder cancer cell line. / Xia, Hong; Bleicher, Richard J.; Gupta, Vicram; Zaren, Howard A.; Singh, Shivendra V.

In: International Journal of Cancer, Vol. 70, No. 5, 17.04.1997, p. 606-611.

Research output: Contribution to journalArticle

Xia, Hong ; Bleicher, Richard J. ; Gupta, Vicram ; Zaren, Howard A. ; Singh, Shivendra V. / Mechanism of increased sensitivity to etoposide in a mitomycin C-resistant human bladder cancer cell line. In: International Journal of Cancer. 1997 ; Vol. 70, No. 5. pp. 606-611.
@article{7a0199aa13284baf8194d35685268815,
title = "Mechanism of increased sensitivity to etoposide in a mitomycin C-resistant human bladder cancer cell line",
abstract = "The mechanism of increased sensitivity to etoposide (VP-16) in a human bladder cancer cell line (J82/MMC-2), which is > 9-fold more resistant to mitomycin C (MMC) compared with parental cells (J82/WT), was investigated. Colony formation assays, following 1 hr drug exposure, revealed that about a 2.2-fold higher concentration of VP-16 was required to kill 50{\%} of the J82/WT cell line compared with J82/MMC-2. The MTT assays, following continuous drug exposure, also showed that the J82/MMC-2 cell line was significantly more sensitive to VP-16 compared with J82/WT. Accumulation of VP-16 was significantly higher in the J82/MMC-2 cell line compared with J82/WT at every drug concentration tested. Likewise, intracellular VP-16 retention was significantly higher in the J82/MMC-2 cell line compared with J82/WT when drug uptake was measured as a function of varying incubation time and at a fixed VP-16 concentration. The efflux of VP-16 from the J82/MMC-2 cell line was equivalent to that from J82/WT. In agreement with the results of drug uptake studies, the levels of VP-16-induced protein-DNA complexes were markedly higher in the J82/MMC-2 cell line compared with J82/WT. The catalytic activity of topoisomerase II (topo II) in 0.35 M NaCl nuclear extract of J82/WT cells was equivalent to that of J82 results suggest that the mechanism responsible for the collateral sensitivity of the J82/MMC-2 cell line to VP-16 may be attributable to a relatively higher drug accumulation in this cell line compared with parental cells.",
author = "Hong Xia and Bleicher, {Richard J.} and Vicram Gupta and Zaren, {Howard A.} and Singh, {Shivendra V.}",
year = "1997",
month = "4",
day = "17",
doi = "10.1002/(SICI)1097-0215(19970304)70:5<606::AID-IJC19>3.0.CO;2-A",
language = "English (US)",
volume = "70",
pages = "606--611",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Mechanism of increased sensitivity to etoposide in a mitomycin C-resistant human bladder cancer cell line

AU - Xia, Hong

AU - Bleicher, Richard J.

AU - Gupta, Vicram

AU - Zaren, Howard A.

AU - Singh, Shivendra V.

PY - 1997/4/17

Y1 - 1997/4/17

N2 - The mechanism of increased sensitivity to etoposide (VP-16) in a human bladder cancer cell line (J82/MMC-2), which is > 9-fold more resistant to mitomycin C (MMC) compared with parental cells (J82/WT), was investigated. Colony formation assays, following 1 hr drug exposure, revealed that about a 2.2-fold higher concentration of VP-16 was required to kill 50% of the J82/WT cell line compared with J82/MMC-2. The MTT assays, following continuous drug exposure, also showed that the J82/MMC-2 cell line was significantly more sensitive to VP-16 compared with J82/WT. Accumulation of VP-16 was significantly higher in the J82/MMC-2 cell line compared with J82/WT at every drug concentration tested. Likewise, intracellular VP-16 retention was significantly higher in the J82/MMC-2 cell line compared with J82/WT when drug uptake was measured as a function of varying incubation time and at a fixed VP-16 concentration. The efflux of VP-16 from the J82/MMC-2 cell line was equivalent to that from J82/WT. In agreement with the results of drug uptake studies, the levels of VP-16-induced protein-DNA complexes were markedly higher in the J82/MMC-2 cell line compared with J82/WT. The catalytic activity of topoisomerase II (topo II) in 0.35 M NaCl nuclear extract of J82/WT cells was equivalent to that of J82 results suggest that the mechanism responsible for the collateral sensitivity of the J82/MMC-2 cell line to VP-16 may be attributable to a relatively higher drug accumulation in this cell line compared with parental cells.

AB - The mechanism of increased sensitivity to etoposide (VP-16) in a human bladder cancer cell line (J82/MMC-2), which is > 9-fold more resistant to mitomycin C (MMC) compared with parental cells (J82/WT), was investigated. Colony formation assays, following 1 hr drug exposure, revealed that about a 2.2-fold higher concentration of VP-16 was required to kill 50% of the J82/WT cell line compared with J82/MMC-2. The MTT assays, following continuous drug exposure, also showed that the J82/MMC-2 cell line was significantly more sensitive to VP-16 compared with J82/WT. Accumulation of VP-16 was significantly higher in the J82/MMC-2 cell line compared with J82/WT at every drug concentration tested. Likewise, intracellular VP-16 retention was significantly higher in the J82/MMC-2 cell line compared with J82/WT when drug uptake was measured as a function of varying incubation time and at a fixed VP-16 concentration. The efflux of VP-16 from the J82/MMC-2 cell line was equivalent to that from J82/WT. In agreement with the results of drug uptake studies, the levels of VP-16-induced protein-DNA complexes were markedly higher in the J82/MMC-2 cell line compared with J82/WT. The catalytic activity of topoisomerase II (topo II) in 0.35 M NaCl nuclear extract of J82/WT cells was equivalent to that of J82 results suggest that the mechanism responsible for the collateral sensitivity of the J82/MMC-2 cell line to VP-16 may be attributable to a relatively higher drug accumulation in this cell line compared with parental cells.

UR - http://www.scopus.com/inward/record.url?scp=0030944854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030944854&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19970304)70:5<606::AID-IJC19>3.0.CO;2-A

DO - 10.1002/(SICI)1097-0215(19970304)70:5<606::AID-IJC19>3.0.CO;2-A

M3 - Article

C2 - 9052763

AN - SCOPUS:0030944854

VL - 70

SP - 606

EP - 611

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -